Because of the development of newer fluoroquinolones with inproved activity against gram-positive organisms, we elected to compare the inhibitory properties of ofloxacin, temafloxacin, sparfloxacin, PD131628, PD127391, and WIN57273 against 105 ciprofloxacin-resistant staphylococci. Based on comparison of MICs for 90% of the organisms (MIC9s), WIN57273 was the most active agent against oxacillin-resistant Staphylococcus aureus; the MIC90 was 0.5 ,ig/ml. Against oxacilHin-resistant, coagulase-negative staphylococci, PD127391 and WIN57273 were the most active agents; the MIC9 was 0.5 ,ug/ml. Against isolates of staphylococci for which ciprofloxacin MICs were .32 jig/m, WVIN57273 and PD127391 still exhibited high activity, inhibiting 100 and 95% of the isolates, respectively, at 2 ,ug/ml. The spontaneous mutation rates for ciprofloxacin-susceptible staphylococci were lowest for ofloxacin. The frequency of spontaneous mutations of ciprofloxacin-resistant staphylococci was low; however, the MICs of PD127391 and WIN57273 for these mutant isolates were greater than 2 ,ug/mI. WIN57273 and PD127391 are two potent new quinolones with high levels of activity against highly ciprofloxacin-resistant staphylococci. There is, however, a major concern of selection of spontaneous mutants resistant to these newer agents.
The 4-quinolone ciprofloxacin appeared to be a promising agent in the treatment of staphylococcal infections because of its activity against methicillin-resistant strains (9, 11, 16) . However, reports of emerging resistance of the staphylococci to ciprofloxacin are increasing (4, 7, (13) (14) (15) . We observed in our 1990 clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococcus spp. a 25 and 27% resistance to ciprofloxacin, respectively. Because of the development of newer fluoroquinolones with improved activity against gram-positive organisms, we elected to compare the inhibitory properties of these agents against 105 oxacillin-and ciprofloxacin-resistant staphylococci. The agents we compared were ofloxacin (2), temafloxacin (A-62254) (1), sparfloxacin (CI-978; AT-4140) (2), PD127391 (CI-960) [7-(3- MICs were determined by microdilution according to standard procedures published by the National Committee for Clinical Laboratory Standards (12) with an inoculum prepared from early to mid-logarithmic-phase growth and adjusted to provide a final inoculum of approximately 5 x 105 CFU/ml (12) . The MIC was defined as the lowest concentration of an antimicrobial agent inhibiting visible growth after overnight incubation at 35°C.
To determine the frequencies of spontaneous mutations to the newer quinolones, inocula of approximately 109 CFU were plated onto Mueller-Hinton agar containing the quinolones at four and eight times the MIC. Three strains of ciprofloxacin-susceptible staphylococci and two strains of ciprofloxacin-resistant staphylococci were studied. Colonies emerging over the first 48 h of incubation at 35°C were subjected to MIC testing.
A total of 105 isolates were tested; 63 were oxacillinresistant S. aureus, and 42 were oxacillin-resistant, coagulase-negative staphylococci. All isolates were resistant to ciprofloxacin; MICs ranged from 4 to >128 ,ug/ml. The range of MICs and MICs for 50 and 90% of the organisms (MIC50s and MIC90s, respectively) of the quinolones studied are shown in Table 1. WIN57273 and PD127391 were the most active of the quinolones tested based on comparison of their MIC90s.
Sparfloxacin and PD131628 showed better activity against the ciprofloxacin-resistant isolates than ofloxacin or temafloxacin but were less active than WIN57273 and PD127391. Against the oxacillin-resistant S. aureus isolates, WIN57273 had the best activity; the MIC90 was 0.5 ,ug/ml.
PD127391 and WIN57273 were the most active agents against oxacillin-resistant, coagulase-negative staphylococci; MIC90s were 0.5 ,ug/ml. Both agents were 16 times more active than sparfloxacin and PD131628 and 64 times more active than ofloxacin and temafloxacin against ciprofloxacinresistant staphylococci. We also compared the activity of each quinolone against staphylococci for which ciprofloxacin MICs were . 16 ,ug/ml and those for which ciprofloxacin MICs were -32 ,ug/ml. Of the 105 isolates ciprofloxacin MICs for 68 were s16 ,ug/ml and MICs for 37 were .32 ,ug/ml. There were only minor differences between quinolone activity against the two staphylococcal groups. WIN57273 and PD127391 exhibited high activity against staphylococci for which ciprofloxacin MICs were .32 ,ug/ml, inhibiting 100 and 95%, respectively, at 2 ,ug/ml. Table 2 gives a comparison of spontaneous mutation rates for the newer quinolones against three strains of ciprofloxacin-susceptible staphylococci. The mutation rates were lowest for ofloxacin. The growth of numerous tiny-colony variants was noted with sparfloxacin and WIN57273 at four times the MIC, which greatly affected their respective mutation rates. The variant colonies, however, were not present at eight times the MIC. None of the quinolone MICs for the spontaneous mutants of ciprofloxacin-susceptible staphylococci were greater than 2 ,ug/ml.
The spontaneous mutation rates for PD127391 and WIN57273 against two strains of ciprofloxacin-resistant staphylococci are shown in Table 3 . Only PD127391 and WIN57273 were tested for frequencies of spontaneous single-step mutations because resistance had already been demonstrated to the other remaining quinolones.
The frequency of spontaneous single-step mutations of ciprofloxacin-resistant staphylococci was low; however, the MICs of PD127391 and WIN57273 to these mutant isolates were greater than 2 ,ug/ml. One colony of oxacillin-and ciprofloxacin-resistant, coagulase-negative staphylococci was found at eight times the MIC of WIN57273 which exhibited a WIN57273 MIC of 32 ,ug/ml and a PD127391 MIC of 4 ,ug/ml.
The newer fluoroquinolones exhibit excellent activity against ciprofloxacin-susceptible staphylococci, as noted in Table 2 . Their activity against ciprofloxacin-resistant staphylococci was the focus in this study. WIN57273 and PD127391 proved to be the most active agents against these resistant isolates. Thomson and others reported PD127391 to be 128-to .512-fold more active than ciprofloxacin against ciprofloxacin-resistant staphylococci (17). Goldstein and others described WIN57273 to be 50-to 100-fold more active than other fluoroquinolones against ciprofloxacin-resistant S. aureus (6) . Both antimicrobial agents are chemically similar to ciprofloxacin. WIN57273 differs only in the presence of a 2,6-dimethylated pyridinyl moiety rather than a piperazinyl moiety at position 7 of the quinolone nucleus (8) . PD127391 differs from ciprofloxacin by the presence of a 3-amino-pyrrolidinyl moiety at position 7 of the quinolone nucleus. In addition, there is a chloride at position 8. The position 7 modifications are responsible for the increased activity of these agents against gram-positive organisms.
Several conclusions were drawn from the studies on the development of spontaneous resistance to the fluoroquinolones. The frequencies of spontaneous single-step mutations selected by the quinolones at eight times the MIC were generally low. There did not appear to be a higher frequency of spontaneous mutations with ciprofloxacin-resistant staphylococci than with ciprofloxacin-susceptible staphylococci.
MICs of PD127391 and WIN57273 for spontaneous mutants of ciprofloxacin-resistant staphylococci were greater than 2 ,ug/ml. The final point is important, as it may signify the possible appearance of WIN57273-or PD127391-resistant staphylococci should the drugs enter clinical trials.
In summary, WIN57273 and PD127391 are two potent new quinolones with high levels of activity against highly resistant staphylococci; however, the selection of spontaneous single-step resistant mutants raises a major concern about the utility of these agents against oxacillin-and ciprofloxacin-resistant staphylococci.
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